The U.S. Supreme Court upheld access to the abortion pill mifepristone, ruling against an anti-abortion physician group’s challenge. The FDA-approved drug, along with misoprostol, is used for abortion up to 10 weeks gestation. The court determined the group lacked legal standing to challenge the FDA’s regulation of the drug. Medical associations praised the decision, emphasizing the importance of maintaining access to safe and effective healthcare treatments. Leaders in reproductive healthcare also welcomed the ruling, highlighting the relief felt nationwide. The decision protects patient-physician relationships and safeguards access to essential treatments, preventing potential negative consequences from limiting access to mifepristone.
Source link
How Healthcare Leaders Are Reacting to the Supreme Court Preserving Abortion Pill Access
